New investigational drug for newly-diagnosed MGMT unmethylated glioblastoma

Trial ID:
IRB-24-8483
Tresa McGranahan, MD PhD

Inclusion Criteria

Patients must:

  • Be a man or woman 18 years of age or older
    Have no prior treatment for GBM, other than surgical resection or biopsy
    Have normal blood pressure or adequately treated and controlled hypertension
    Be able to undergo MRI brain with intravenous (IV) contrast

Exclusion Criteria

Patients must not:

  • Have metastatic or predominant leptomeningeal disease
    Have current active pneumonitis or any history of pneumonitis within 90 days of start of study
    Have a history of another malignancy within 2 years

Additional Info

Study visits include health checks, tests, medication diaries and questionnaires. All study visits will be scheduled at Scripps Clinic Torrey Pines or Prebys Cancer Center in Hillcrest. Participants may continue to take the niraparib or TMZ as long as the cancer does not get worse or completion of 6 cycles of treatment (TMZ).

More information can be found at clinicaltrials.gov using NCT06388733.

Contact Info:

  • Clinical Research Services
  • CRSLeadership@scrippshealth.org